Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Haining WangYe LiuQing TianJin YangRan LuSiyan Zhan Jari K Haukka Tianpei Hong

Published in: Diabetes, obesity & metabolism (2018)

Treatment with incretin drugs was not associated with an increased risk of pancreatic cancer in people with T2DM. Instead, it might protect against pancreatic malignancy in patients treated for ≥104 weeks.

Keyphrases

systematic review
type diabetes
metabolic syndrome
replacement therapy
weight loss
glycemic control
smoking cessation
preterm birth